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correlate with synovitis reduction
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Abstract
Background: Braces are used to treat pain in patellofemoral joint osteoarthritis (PFJOA). In a trial, we previously
reported pain improvement after 6-weeks brace use. The pain reduction did not correlate with changes in Magnetic
Resonance Imaging (MRI) assessed Bone Marrow Lesion volume or static synovial volume. Studies show that
changes in the synovium on dynamic contrast enhanced (DCE) MRI are more closely associated with
symptom change than static synovial volume changes. We hypothesised change in synovitis assessed using
dynamic imaging could explain the reduction in pain.
Method: One hundred twenty-six men and women aged 40–70 years with painful radiographically confirmed PFJOA
were randomised to either brace wearing or no brace for 6-weeks. Pain assessment and DCE-MRI were performed at
baseline and 6 weeks. DCE data was analysed using Tofts’s equation. Pain measures included a VAS of pain on
nominated aggravating activity (VASNA), and the KOOS pain subscale. Paired t-tests were used to determine
within person change in outcome measures and Spearman’s correlation coefficients were used to determine
the correlation between change in pain and change in the DCE parameters.
Results: Mean age of subjects was 55.5 years (SD = 7.5) and 57% were female. There was clear pain
improvement in the brace users compared to controls (VASNA − 16.87 mm, p = <0.001). There was no
significant change to the dynamic synovitis parameters among brace users nor was pain change correlated
with change in dynamic synovitis parameters.
Conclusion: The reduction in knee pain following brace wearing in patients with PFJOA is not explained by
changes in synovitis.
Trial registration: Trial registration number UK. ISRCTN50380458/Registered 21.5.2010.
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Background
Patello-femoral Joint Osteoarthritis (PFJOA) is a common
cause of knee pain in middle aged adults. In a recent ran-
domised controlled trial of brace therapy in persons with
symptomatic PFJOA we showed that a flexible sleeve knee
brace resulted in a significant improvement in pain after
6 weeks and a reduction in bone marrow lesion (BML)
volume in the PFJ [1]. The two structures in the knee that
are both innervated by nociceptive fibers and reported to
be causally related to knee pain are bone [2] and synovitis
[3, 4]. In the bone, the most prominently assessed abnor-
mality correlated with pain has been bone marrow lesions
[5]. While hyaline cartilage pathology is the signature fea-
ture of osteoarthritis [6], this cartilage is not innervated,
and it is not clear whether it is a source of pain. The
change in pain during the trial was not correlated signifi-
cantly with change in the BML volume, suggesting other
mechanisms explain the pain reduction. Synovial tissue
volume decrease has been linked with pain in observational
studies [3, 4], but synovial volume assessed in the trial
using static contrast enhanced magnetic resonance imaging
(CE-MRI) did not shrink with the intervention [1].
Static measures of synovial volume may be less sensitive
to pain than measures of synovial perfusion, assessed
using dynamic contrast enhanced Magnetic Resonance
Imaging (DCE-MRI) is a technique that utilises repeated
imaging sequences of the joint whilst injecting contrast
agent systemically [7]. This allows enhancement rates of
tissues to be calculated as they are perfused by contrast
agent. The rate of tissue enhancement has been shown to
be more closely linked to active joint inflammation in
rheumatoid arthritis (RA) than changes to static tissue
volume measures alone, and correlates more strongly with
change in pain following intra-articular steroid therapy
[8]. We have recently shown that in knee OA, intraarticu-
lar steroid treatment leads to a major reduction in perfu-
sion of the synovium as shown by DCE-MRI and that this
reduction is far better correlated with pain reduction than
measures of static synovial volume [9]. Since braces may
diminish contact stress across the joint, leading to less
microscopic damage and perhaps less need for the syno-
vium to clear this debris, we hypothesised that the reduc-
tion in pain observed following brace use in our recent
trial might be explained by changes in synovitis as assessed
using DCE-MRI parameters. We therefore undertook
a secondary analysis of the trial findings to examine
this question.
Methods
Design
One hundred twenty-six subjects aged 40–70 years, re-
cruited from primary and secondary care were randomly
allocated to receive a patello-femoral sleeve brace imme-
diately for 6 weeks or no brace. DCE-MRI was performed
at both baseline (0 weeks) and at 6 weeks for all subjects.
The number of subjects was chosen in advance to provide
80% power to detect an effect of the brace on knee pain
(alpha = 0.05, two sided). Recruitment took place between
August 2009 to September 2012 and the trial’s main re-
sults have been reported elsewhere [1]. The primary struc-
tural outcome of the brace trial was bone marrow lesion
(BML) volume but pain improvement was not signifi-
cantly correlated with change in BML volume. Our dis-
covery after intraarticular steroid injection that dynamic
changes in synovium during DCE-MRI correlated with
pain change led us to ask the question as to whether these
dynamic changes in synovial volume explained the pain
change in the knee brace study as a secondary analysis of
these trial data.
Inclusion/exclusion criteria
Subjects were included if they had knee radiographs with
a Kellgren and Lawrence (KL) score of grade 2 or 3 in
the PFJ. This had to be greater than the KL grade for the
tibiofemoral joint. Subjects had daily pain for the pre-
vious 3 months which was sufficiently severe to score 40
or above on a 0–100 mm for the visual analogue scale of
pain on nominated aggravating activity (VASNA), and
have PF symptoms (such as pain with stairs). Other inclu-
sion/exclusion criteria for eligibility have been reported
[1]. As contrast enhanced scans were used, subjects with
renal dysfunction or undergoing dialysis were excluded.
Intervention
Subjects remained on their usual OA treatment. The
intervention consisted of a Bioskin Patellar Tracking Q
Brace (Ossur UK, Manchester, England). This is a Lycra
flexible knee support with an optional strap that can be
pulled over the patella; no difference in efficacy between
the strapped and unstrapped configuration has been re-
ported [10]. Simple randomisation was carried out by
the study statistician with allocation using opaque enve-
lopes. There is no known minimal required use to obtain
the therapeutic effect of a knee brace, and we arbitrarily
chose at least 4 h/day, so that if randomised to brace
therapy, participants were instructed to wear it for a
minimum of 4 h daily.
Assessments
Knee pain
Following subject recruitment and randomisation, both
groups completed questionnaires evaluating their PFJ
pain and imaging with DCE-MRI. After 6 weeks, pain
evaluation and DCE-MRI was repeated for all subjects in
both groups. The primary symptom outcome measure
was pain on a VASNA (0 mm = no pain, 100 mm = worst
pain) and the Knee Osteoarthritis Outcome Score (KOOS)
pain scale was a secondary outcome measure.
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Outcome measures: Structural
MRI assessment
DCE-MRI variables were collected for all subjects at
baseline and after 6 weeks using the same magnet and
scanning protocol. The enrolled knee only was scanned.
Using a 1.5 T Philips Gyroscan ACS NT (Philips, Best
Netherlands), axial proton density weighted (PDW) fat
saturated (FS) repetition time approximately (TR) 5.5 ms,
echo time approximately (TE) 1.9 ms, field of view (FOV)
14 cm × 14 cm, 256 × 256 matrix, slice thickness 3 mm
sequences were obtained in all subjects, under the gui-
dance of a musculoskeletal radiologist. The contrast agent
Dotarem (gadoteric acid) was administered intravenously.
MRI analysis
The synovitis was segmented on the sagittal image, per-
formed blinded, with computer image analysis excluding
cartilage within the segmented area and calculating the
proportion of synovial tissue within every voxel [11].
The segmentation was transferred onto the dynamic image
using image registration techniques. Repeated MRI se-
quences were performed every 22 s, and contrast was
injected following the 3rd sequence. In our analysis the
primary outcome measure was change in enhancement
rates of synovium between the baseline and 6-week visit.
These variables act as a quantitative assessment of the
change in severity of knee synovitis.
Three DCE parameters used in this study were calcu-
lated from analysis of the synovial enhancement curve
(EC) (Fig. 1) and one was calculated from the Standard
Tofts’s equation [12]. The relative enhancement rate
(RER) is a measurement the initial slope of the EC, which
is sensitive to synovial vascularity and capillary permeabi-
lity which reflects inflammatory activity. The maximum
relative enhancement (REmax) and late relative enhance-
ment (RElate) were also measured from the EC. K
trans, the
volume transfer coefficient calculated from Tofts’s equa-
tion, also depends on synovial vascularity and capillary
permeability. It is thought as synovitis severity increases,
DCE parameters will increase correspondingly [8, 12].
Statistical analysis
Our analyses included a comparison of the brace and no
brace groups from baseline to 6-weeks. Change in pain
(VASNA and KOOS pain subscale) and the four DCE pa-
rameters were assessed by paired t-tests. Following this,
unpaired t-tests were performed to identify differences
in within person change between brace and control groups.
Only subjects with complete data sets at each time point
were included in analysis. In addition, bivariate Pearson’s
correlation coefficients were performed to quantify the
strength of associations between change in pain and
change in the DCE outcomes in the brace group. The sta-
tistical analysis was performed using Stata (V.13.1; Stata
Corporation, College Station, Texas, USA).
Results
Subjects
One hundred twenty-six subjects were recruited; 63 were
randomised to the intervention and 63 the control group
(Fig. 2). The mean age of subjects in the intervention group
was 54.5 years (SD = 6.7), body mass index (BMI) was 31.4
Kg/m2 (SD = 6.3) and 63.5% were female. The control
group had a mean age of 56.4 years (SD = 8.1), BMI of
Fig. 1 An example of a typical enhancement curve of a voxel of synovium during and post the administration of contrast agent. Three dynamic
enhancement parameters are calculated from analysis of the enhancement curve; these variables (RER, REmax and RElate) are labelled on the curve.
The x-axis is time in seconds. There are 22 s between each plotted point on the enhancement curve. The y-axis shows signal intensity, starting at zero
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30.5 Kg/m2 (SD = 5.1), and 50.8% were female. Baseline
pain was similar in both groups (mean VASNA 6.5). The
brace group showed a mean pain reduction of 1.8 on the
10 cm VAS vs. 0 for the no brace group. The mean time
the brace was worn was 7.35 h/day (SD = 3.10).
Between group change in pain and synovitis
There was a significantly greater within person reduction in
pain in the brace users compared to the controls over the
6-week period (VASNA p < 0.001, KOOS pain p = 0.01)
(Table 1). In contrast there was no significant difference in
within person change in most DCE-MRI parameters be-
tween the treated and control group. There was a significant
between group difference in the within-group change in
RER (RER change 0.008, p = 0.02), however, this was pri-
marily due to the significant improvement in the control
group (implying reduction in synovitis) rather than a posi-
tive change in RER seen in the intervention group (Table 2).
Within group change in pain and DCE parameters
A significant reduction in the VASNA score (−18.16,
p < 0.001) and an increase in the KOOS (8.78, p < 0.001)
Fig. 2 CONSORT Diagram for the BRACE trial’s 6 week period
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after 6 weeks brace use, signifying a reduction in pain.
However, there were no significant changes to the DCE
parameters in this group (Table 2). There was no statisti-
cally significant change to pain experienced over 6 weeks
in the control group (VASNA p = 0.61, KOOS pain
p = 0.31). There were small but significant changes noted
to two of the DCE parameters in the control group; the
mean change of Ktrans was −0.003 (p = 0.05) and RER was
−0.005 (p = 0.04), a reduction in enhancement rates of the
synovium, suggesting a reduction in synovitis (Table 2).
Pearson’s correlations showed weak correlations bet-
ween change in the dynamic parameters and the two
pain measures (r = −0.10 to 0.12).
Discussion
Our result suggest that synovitis, assessed using a sensi-
tive imaging technique, does not improve following
sleeve brace wearing. Change in synovitis does not ex-
plain the observed improvement in pain. Within the
control group there was a small reduction in RER
(p = 0.04) and Ktrans (p = 0.05) variables over the study
period suggesting a reduction in synovitis in this group,
however, the magnitude of the changes was small and
probably not clinically significant.
The DCE technique is a more sensitive method of de-
tecting synovitis than static contrast enhanced imaging.
Axelsen et al. demonstrated in 17 RA patients that intra-
operative knee synovial biopsies showed histological in-
flammation which was highly correlated with changes in
rates of synovial enhancement on pre-surgical T1 weighted
MR images, especially the RER (spearman’s correlation co-
efficient = 0.70, p = 0.001) [8]. A review by Hodgson et al.
was consistent with this; the RER was shown in multiple
RA studies to correlate with histological, physiological
and clinical disease activity changes [13]. Synovitis
assessed using DCE-MRI was more strongly associated
with change in pain following steroid injection than
static MRI imaging [14].
As noted earlier, the two structures consistently linked
to pain in knee OA have been bone marrow lesions and
synovitis (bone attrition has also been linked to pain but
would be unlikely to change in 6 weeks and its change is
not readily measurable). The absence of any association
with change in synovitis assessed using DCE-MRI sug-
gests that the reduction in pain following brace wearing
is not due to change in synovitis and that other mecha-
nisms may be operating. What then is the mechanism
for pain reduction? We did find in the trial that the pa-
tellar brace caused a reduction in BML volume in the
Table 2 Subject baseline characteristics, mean within-group change following intervention with brace and in controls (without brace),
and between-group differences in change (pre- and post-intervention)
Controls (N = 63 randomised, 62 attended
6 week visit)
Brace group (N = 63 randomised, 58 attended
6 week visit)
Brace group - controls
Variable N in
analysis
Mean change within
group, (95% CI)
P-value N in
analysis
Mean change within
group, (95% CI)
P-value Mean change within
group, (95% CI)
P-value
VASNA 58
a −0.13 (−0.64 to 0.38) 0.61 56a −1.82 (−2.39 to −1.24) <0.001 1.69 (0.93 to 2.44) <0.001
KOOS pain 61a 1.71 (−1.66 to 5.08) 0.31 57a 8.78 (4.36 to 13.20) <0.001 −7.06 (−12.52 to −1.61) 0.01
Ktrans 48 −0.003 (−0.006 to 0.000) 0.05 39 0.001 (−0.003 to 0.005) 0.63 −0.004 (−0.009 to 0.001) 0.11
RER 48 −0.005 (−0.010 to 0.000) 0.04 39 0.003 (−0.002 to 0.008) 0.19 −0.008 (−0.014 to −0.001) 0.02
RElate 47
b −0.102 (−0.280 to 0.076) 0.25 39 0.010 (−0.175 to 0.195) 0.91 −0.112 (−0.367 to 0.142) 0.38
REmax 48 −0.161 (−0.357 to 0.036) 0.11 39 0.045 (−0.166 to 0.256) 0.67 −0.206 (−0.491 to 0.079) 0.15
aNumber of observations for KOOS and VASNA are less than the number attending week 6 visit due to incomplete questionnaires.
bDynamic data model error
prevented the use of one RElate observation
The reduction in RER represents a reduction in the rate of enhancement and was seen significantly more often in the control group, not in the treatment group
Table 1 Subject baseline characteristics - mean pain scores and DCE parameters of subjects in each group
Controls (N = 63 randomised, 62 attended 6 week visit) Brace group (N = 63 randomised, 58 attended 6 week visit)
Variable N in analysis Baseline ean (SD) 6 week visit mean (SD) N in analysis Baseline mean (SD) 6 week visit mean (SD)
VASNA 58
a 6.17 (2.20) 6.30 (2.14) 56a 5.02 (2.55) 6.83 (2.13)
KOOS pain 61a 53.03 (18.27) 51.32 (18.30) 57a 57.72 (22.93) 48.94 (18.36)
Ktrans 48 0.016 (0.018) 0.019 (0.018) 39 0.018 (0.018) 0.017 (0.014)
RER 48 0.034 (0.015) 0.039 (0.020) 39 0.038 (0.018) 0.035 (0.010)
RElate 47
b 2.084 (0.846) 2.186 (0.870) 39 2.128 (0.874) 2.118 (0.634)
REmax 48 2.474 (0.880) 2.635 (0.945) 39 2.569 (0.961) 2.523 (0.639)
aNumber of observations for KOOS and VASNA are less than the number attending week 6 visit due to incomplete questionnaires
bDynamic data model error prevented the use of one RElate observation
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patellofemoral compartment but that reduction was not
significantly correlated with pain reduction. Although
change in BML volume did not explain the pain reduction,
it is possible that change in other structural features may
have contributed. Ultimately, while pain improved, this
was not necessarily accompanied by structural changes
(although we may not have had the power to show that
the reduction in BML volume was correlated with the pain
reduction). The decrease in focal stress across the patel-
lofemoral joint may have decreased nociceptive stimuli
without causing a change in imaging parameters, and it is
possible that our imaging approaches to pain are still too
insensitive to detect the change induced.
This study was a secondary analysis of a trial of 126
patients. The original design did not include a formal
sample size calculation for the DCE-MRI analysis. In-
stead, we made use of all available DCE-MRI scans col-
lected during the course of the trial. Given the observed
DCE-MRI trial data, we can calculate an estimated sam-
ple size for a future trial of the same design. Using RER
as the primary outcome, the observed RER values for the
change in the brace (mean change = +0.003; SD = 0.014)
and no-brace group (mean change = −0.005; SD = 0.016),
alpha of 0.05 and 80% power, a parallel-groups clinical
trial testing for differences in the change in RER between
the brace and no-brace group after 6 weeks would require
59 patients per group, a similar number to the trial fin-
dings presented here. A design using Ktrans as the primary
outcome, using observed values for the brace and no-
brace group, would require 137 patients per group. Based
on these estimates, it is possible but unlikely that our
study was null because of inadequate power. We note that
we found significant effects of dynamic measures of syno-
vitis but in the opposite direction expected and that pain
reduction effects were highly statistically significant.
The reduction in pain seen in the trial was modest but
exceeded the minimum clinically important difference
reported by Angst et al. (1.3 on a 10 cm scale) [15].
There are some limitations to be considered. It is pos-
sible that the six weeks trial duration may not have been
long enough to identify significant physiological changes
to synovium in participants who used a brace. This
seems unlikely as changes are seen within 2-weeks fol-
lowing an intra-articular steroid injection [11, 16]. DCE-
MRI was taken from a fixed region of interest (ROI) in
the knee set on computer software. This is due to the
standard Tofts’s equation requirements and the need to
select a fixed area of tissue to make each image compa-
rable between subjects. As each participant did not have
the same size knee, the ROI varied between participants.
This may have led to the fixed ROI window not captur-
ing all the synovitis in each knee. This discrepancy was
not recorded; there may be a difference between the
groups with the percentage of total synovitis measured.
In addition, sampling was done at intervals longer than
might be optimal to detect dynamic change. The low
temporal resolution of the DCE-MRI sequence (22 s)
limits the accuracy of the model, particularly for estimat-
ing Ktrans. The field of view (FOV) was also limited
reflecting the compromise in DCE-MRI between tem-
poral resolution, spatial resolution and FOV in the phase
encode directions; these could be improved for measure-
ment of RElate where high temporal resolution is less im-
portant. Also, movement between dynamic images may
degrade reproducibility of measurements such as RER.
This could be reduced by use of image registration (4).
Conclusion
Brace therapy in symptomatic knee PFJOA is linked in
the short term with a reduction in knee pain. There was
no corresponding reduction in the observed DCE-MRI
parameters of knee synovitis.
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